Home › Funds › Troluce Capital Advisors LLC › STOK
Troluce Capital Advisors LLC position in STOK
STOKE THERAPEUTICS INC · Health Care
Troluce Capital Advisors LLC reported holding 806,108 shares of STOK (STOKE THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$21.0M, representing 2.83% of its reported portfolio and ranking #13 among its reported holdings. Troluce Capital Advisors LLC has disclosed STOK holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Troluce Capital Advisors LLC's STOK position evolved
Troluce Capital Advisors LLC first disclosed a stake in STOK in Q1 2026 at 652,800 shares (US$21.3M). Across 3 filings, Troluce Capital Advisors LLC increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 806,108 shares valued at US$21.0M — an increase of 309,692 shares quarter over quarter.. Notable position changes include a 62% increase in Q3 2026 (shares rose 2% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 652.80K | $21.26M | New |
| Q2 2026 | 496.42K | $16.24M | Reduce |
| Q3 2026 | 806.11K | $20.96M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About STOK and 13F data
STOK (STOKE THERAPEUTICS INC) is a Health Care company. 47 other funds we track also report a position in STOK — the largest reported positions include RTW INVESTMENTS, LP (US$146.2M), Lynx1 Capital Management LP (US$101.3M), Redmile Group, LLC (US$100.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding STOK
- RTW INVESTMENTS, LP 5.62M sh · $146.21M · Q3 2026
- Lynx1 Capital Management LP 3.90M sh · $101.30M · Q3 2026
- Redmile Group, LLC 3.87M sh · $100.59M · Q3 2026
- BVF INC/IL 3.61M sh · $93.83M · Q3 2026
- Siren, L.L.C. 2.00M sh · $51.88M · Q3 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 1.82M sh · $47.41M · Q3 2026
- BAKER BROS. ADVISORS LP 1.31M sh · $34.16M · Q3 2026
- MPM BioImpact LLC 925.13K sh · $24.05M · Q3 2026
- Opaleye Management Inc. 700.00K sh · $22.90M · Q2 2026
- EcoR1 Capital, LLC 835.00K sh · $21.71M · Q3 2026
- Vestal Point Capital, LP 345.00K sh · $8.97M · Q3 2026
- TANG CAPITAL MANAGEMENT LLC 300.00K sh · $7.80M · Q3 2026
More on Troluce Capital Advisors LLC
FAQ
How long has Troluce Capital Advisors LLC held STOK?
Troluce Capital Advisors LLC has disclosed STOK holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
What is Troluce Capital Advisors LLC's current position in STOK?
As of Q3 2026, Troluce Capital Advisors LLC holds 806.11K shares of STOK (STOKE THERAPEUTICS INC), valued at $20.96M, representing 2.83% of its reported portfolio and ranking #13.
Has Troluce Capital Advisors LLC been buying or selling STOK?
In the latest 13F filing (Q3 2026), Troluce Capital Advisors LLC increased its position in STOK.
Which other funds hold STOK?
Other major institutional holders of STOK include RTW INVESTMENTS, LP, Lynx1 Capital Management LP, Redmile Group, LLC, among 47 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.